Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Joseph McGuire was terminated as Chief Financial Officer at MAIA Biotechnology, Inc..
- Action
- terminated
- Role
- Chief Financial Officer
Exact text from the filing
On November 10, 2023, Joseph McGuire and Dr. Mihail Obrocea were terminated from their positions as Chief Financial Officer (and principal financial and accounting officer) and Chief Medical Officer, respectively, of the Company, effective immediately, as part of the Company’s effort to streamline operations.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Mihail Obrocea was terminated as Chief Medical Officer at MAIA Biotechnology, Inc..
- Action
- terminated
- Role
- Chief Medical Officer
Exact text from the filing
On November 10, 2023, Joseph McGuire and Dr. Mihail Obrocea were terminated from their positions as Chief Financial Officer (and principal financial and accounting officer) and Chief Medical Officer, respectively, of the Company, effective immediately, as part of the Company’s effort to streamline operations.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jeffrey Himmelreich was appointed as Head of Finance at MAIA Biotechnology, Inc..
- Action
- appointed
- Role
- Head of Finance
Exact text from the filing
On the same date, the Company appointed Jeffrey Himmelreich as its Head of Finance and principal financial and accounting officer.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
MAIA Biotechnology, Inc. terminated Sales Agreement with ThinkEquity LLC valued at upsize total offering amount of up to $7,000,000; gross proceeds of $1,667,084.40 from sale of 758,3 (effective 2023-11-15).
- Action
- termination
- Agreement
- atm program
- Counterparty
- ThinkEquity LLC
- Value
- upsize total offering amount of up to $7,000,000; gross proceeds of $1,667,084.40 from sale of 758,3
- Effective
- 2023-11-15
Exact text from the filing
On November 15, 2023, MAIA Biotechnology, Inc. (the “Company”) suspended sales of its common stock, par value $0.0001 per share (“Common Stock”), pursuant to that certain Sales Agreement, dated as of September 1, 2023 (the “Sales Agreement”), between the Company and ThinkEquity LLC (the “Agent”), the Company’s sales agent thereunder, and provided notice to the Agent that it is terminating the Sales Agreement, which termination will be effective 10 days after November 15, 2023, in accordance with the terms of the Sales Agreement.
View on SEC.gov